Dutch move gives boost to EU orphan drug drive
This article was originally published in Scrip
Executive Summary
Developing orphan medicines is fraught with difficulties, particularly as many of these products emerge from niche research conducted by small biotech firms that may not have the resources to leap the many regulatory hurdles on the way to marketing approval.